Information Provided By:
Fly News Breaks for September 2, 2015
TSRO
Sep 2, 2015 | 10:54 EDT
Mizuho analyst Peter Lawson said he sees clear competitive advantages for TESARO's VARUBI. Lawson notes bears could focus on the fact that MEC usage and acute phase usage are not explicitly stated in the drug label's indication, but he believes both are implied and he does not expect the label to limit usage in a drug class that physicians are already familiar with. The analyst keeps a Buy rating and $67 price target on TESARO shares, which are up $4 to $55.69 in intraday trading.
News For TSRO From the Last 2 Days
There are no results for your query TSRO